PREVENTING INFECTIONS IN HIGHER-RISK MYELODYSPLASTIC SYNDROME PATIENTS TREATED WITH HYPOMETHYLATION AGENTS
Hypomethylation agents became the standard of care for patients with high-risk myelodysplastic syndrome (MDS). While long-term benefits of azacitidine (AZA) and decitabine (DEC) were demonstrated in multiple studies, methods to enhance patients’ safety during therapy with those agents are pending. T...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2013-08-01
|
| Series: | European Medical Journal Hematology |
| Subjects: | |
| Online Access: | https://emj.emg-health.com/wp-content/uploads/sites/2/2013/08/EMJ-Hematology.-Yishai-Ofran..pdf |